Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ZLZai Lab Limited logo

Zai Lab Limited (ZLAB)

NASDAQ Global Market · Currency in USD
$24.03 ▲ +1.99 (+9.03%)
At close: Oct 23, 4:00 PM ET. Market closed.
$24.50 ▲ +0.47 (+1.96%)
After hours: Oct 23, 7:39 PM ET

Summary

Previous Close
$22.04
Open
$23.19
Day's Range
$22.23 – $24.50
52 Week Range
$15.96 – $27.50
Volume
3,691,476
Avg. Volume
970,643
Market Cap
$2.70B
Beta (5Y Monthly)
0.83
PE Ratio (TTM)
--
EPS (TTM)
-$1.68
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$53.75

Profile: Zai Lab Limited

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,784
CEO
Ying Du

Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.56 · Revenue est. $108.83M
DateEst.Actual
Aug 6, 2026-$0.68-$0.46Beat
May 7, 2026-$0.53-$0.46Beat
Feb 26, 2026-$0.44-$0.46Miss
Nov 6, 2025-$0.28-$0.33Miss
Aug 7, 2025-$0.37-$0.37Beat
May 8, 2025-$0.50-$0.45Beat

Analyst view

Consensus price target
$53.75 ▲ +123.7%
Range $35.00 – $75.00
Rating: Buy
Buy 82% · Hold 18% · Sell -0%

Similar stocks

Get free alerts on ZLAB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.